™

simply
“beyond”
“beyond”
 Therapeutic development
i n c r i t i ca l ca r e , tac k l i n g o r ga n fa i l u r e s i n r e a l - t i m e w i t h a n
t r e at i ng d i s e a s e s s u c h a s s e p s i s , r e n a l fa i l u r e , r e s p i r ato ry a n d
a b ov e 50% . AMPLYA™ is a c r i t i ca l ca r e m u lt i t h e r a p e u t i c
from the more conventional to adsorption t r e at m e n t s -

Amplya™ for patients

An acute patient in critical care may suffer
from ‘multi-organ failure’ - a crippling and often
lethal condition.
AMPLYA™ offers acute patients:
The most suitable treatment
Personalized
 treatment and fast intervention
Advanced support for organ failure

Amplya™ for critical care staff

AMPLYA™ provides for the needs expressed
of nursing and critical care staff, offering:
The simplicity of one single system to execute the

broadest variety of treatment modalities
The serenity of automated, simple, and round-the-clock
management of complex treatments
A reduction and optimization of operational sequences
and time

Amplya™ for clinicians

AMPLYA™ provides for the needs of clinicians,
offering:
Unique
 therapeutic choice
Advanced and targeted personalisation capability
Complete
 control of the therapeutic process

BE YO N D MAN AG EMENT

WITH A M P LYA ™ , A D VA N C E D A U TO M AT I O N,

M A N AG E M E N T TIMES, and the integration

a single system MAKE IT POSSIBLE TO “GO

has a heart and soul
i n tegrat e d a n d p e r s o n a l i s e d a p p r oac h i s a p r i o r i t y f o r e f f e c t i v e ly
m ulti - o r ga n fa i l u r e : all diseases with m o r ta l i t y r at e s still
s ystem i n t e g r at i n g m u lt i p l e e x t r ac o r p o r e a l m o da l i t i e s -
t hat p r ov i d e s a wider choice for t r e at i n g o r ga n fa i l u r e .

The soul of Amplya™:

selective clearance
Blood is the tissue that connects all organs.
It controls the functionality of each organ by
permitting cellular survival, regulation and
growth. It transports nutrients and removes the
waste products of cellular metabolism.

Complementary use of filtration and adsorption

can remove the molecules involved in organ
damage whilst retaining essential components,
such as albumin, and can encourage
functional recovery of the organ.

AMPLYA™ intervenes in this process by

delivering a specific and targeted treatment
for an individual disease.

The soul of AMPLYA™ is an

innovative concept born
from Collaborative
Research between
University, Hospital
and Industry.

E FFICAC Y A N D E F F I CI E N CY

O P T I M A L C O N TA I N M E N T O F P R E PA R AT I O N A N D

of the b roadest range of modalities into

B E Y O N D ” in managing E FFI CAC Y A N D E FF I C I ENC Y.

T H E R I G H T T
™

HOW
The added value
of Amplya™
COMPLETENESS
Innovative treatments open up new horizons
All kidney replacement modalities
Innovative and specific sorbents
S
 ystemic or locoregional anticoagulation systems
O
 ne single set of lines couplable to six blood filters
L ow- and high-flux treatments
D
 irect and continuous hematocrit and oxygen saturation
measurement
High treatment autonomy thanks to 3 high-capacity scales

AUTOMATION
Dual cassette plug & play system
F ast and safe disposable installation
F ully automated preparation and treatment
P
 ersonalised CPFA® management with controlled
servo-assisted flows
Automatic level control
O
 ptical self-recognition of the single use pre-assembled
device
O
 ver 300 hours of stored data, accessible by on PC

INTUITIVENESS
Touch screen
Immediate operator interface
Flexible operating sequences
O
 ne cassette system for all modalities

For patients suffering from:

ALI (Acute Lung Injury); RHEUMATOID ARTHRITIS;

ARDS (Acute Respiratory Distress Syndrome); COBP
(Chronic Obstructive Bronchopneumopathy); CRUSH
SYNDROME; HYPERCHOLESTEROLEMIA; ARF (Acute
Renal Failure); MYASTHENIA GRAVIS; MYELOMA;
MOF: MULTI-ORGAN DYSFUNCTION (Renal, Hepatic,
Cardiac, Pulmonary And Cerebral); IMMUNE
COMPLEX DISEASES; SEVERE SEPSIS; SEPTIC SHOCK.
H E R A P Y W A Y
 ™

WHAT
A wide therapeutic choice
The h i sto ry o f Bellco i n many ways mirr ors the his tory of ex tracorpor e a l blo o d
p u r i f i cat i o n : c o n sta n t c ommi tmen t and passion toward C olla b orative R e s e a r c h .

A tt e n t i v e n e s s , l i st e n i n g to the needs of the medical and scien tific co m m u n it i e s ,

a lo n g w it h k n ow - h ow and innovative capab ili ty today make it possi bl e to ta k e
a n ot h e r s t e p f o r wa r d o n the r oad to excellence .

c u r r e nt a n d f u t u r e c h a llenges in cri tical care require in tui tive , versat i l e s ys t e m s

a bl e to r e s p o n d to c l i n i cal needs in real - time .

AMPLYA™: A LIFE-SAVING SYSTEM

AMPLYA™ is capable of performing a broad range of extracorporeal blood clearance therapies with
one single circuit.

For each specific disease, an unprecedented integrated therapeutic approach aids patient survival
and improves quality of life.

AMPLYA™: a real and complete

multitherapeutic system.
A single platform for multiple options.

CRRT (SCUF, CVVH, CVVHD, CVVHDF)

IRRT (IHF-HVHF, IHD SLED, IHDF)

P
 EX

CPFA®

C
 ASCADE FILTRATION

C
 O2 REMOVAL (ABYLCAP & ABYLCAP HD)
 ™

BEYOND
Selective clearance:
beyond the known
patterns
As essential components are retained and waste products
eliminated in normal physiological conditions, selective
clearance in pathological conditions can only be truly
effective if it too can retain essential blood components whilst
eliminating toxic ones.

The development of new and more effective clearance

technologies to provide optimal therapeutic support for
complex diseases.

This is the commitment of the Collaborative Research of

universities, clinics and the industry, also testified by the F.A.R.E.
Project: Filtration and Adsorption Regione Emilia-Romagna.
Bibliography
1) B erlot G, et al.
 Coupled Plasma Filtration-Adsorption.
A nnual Update in Intensive Care and Emergency Medicine 2012, J-L.
V  incent (ed.) 653-58 Springer-Verlag Berlin Heidelberg 2012
2) B erlot G, et al.
Changes in microvascular blood flow during coupled plasma filtration
and adsorption.
A naesth Intensive Care 2011; 39: 687-9
3) L ucisano G, et al.
Coupled plasma filtration adsorption for the treatment of a patient
with acute respiratory distress syndrome and acute kidney injury: a case
report.
N  DT Plus (2011) 4: 285-8
4) M  oretti R, et al.
C  oupled plasma filtration-adsorption in Weil’s syndrome: case report.
M  inerva Anestesiol 2011 August; 77(8): 846-9
5) C  aroleo S, et al.
Coupled plasma filtration adsorption reduces serum bilirubine in a case
of acute hypoxic hepatitis secondary to cardiogenic shock.
Int J Artif Organs 2010; 33 (10): 749-52
6) Wratten ML.
Therapeutic approaches to reduce systemic inflammation in septic-
associated neurologic complications.
E ur J Anaesthesiol 2008; 25 (Suppl 42): 1-7
7) F ormica M, et al.
C  oupled plasma filtration adsorption.
C  ontrib Nephrol. 2007; 156:405-10
8) M  ariano F, et al.
Regional citrate anticoagulation in critically ill patients treated with
plasma filtration and adsorption.
B lood Purif 2004; 22:313-9
9) R  onco C, et al.
C oupled plasma filtration adsorption: rationale, technical development
and early clinical experience.
B lood Purif 2003;21:409-16
10) Formica M, et al.
H emodynamic response to coupled plasmafiltration-adsorption in hu-
man septic shock.
Intensive Care Med 2003; 29:703-8
11) Cesano G, et al.
Treatment of septic shock with the use of CPFA (associated plasma
filtration adsorption): impact on hemodynamic monitored with PiCCO.
G Ital Nefrol 2003; 20(3): 258-63
12) Ronco C, et al.
A pilot study of coupled plasma filtration with adsorption in septic shock.
C rit Care Med 2002; 30: 1250-5

ADV. DEPT. 10.2012 IBSPR8001 REV. 02

Bellco S.r.l.
Via Camurana, 1
41037 Mirandola (MO) Italy
Tel: +39 0535 29111
Fax: +39 0535 25501
marketing@bellco.net
www.bellco.net